Months after steering a seizure rescue therapy to market, UCB bags another promising late-stage asset for $125M upfront

UCB has picked up an epilepsy drug-device from a buyout that will cost at most $270 million, tucking a Phase III-ready project and the team …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Months af­ter steer­ing a seizure res­cue ther­a­py to mar­ket, UCB bags an­oth­er promis­ing late-stage as­set for $125M up­front